Tech billionaires are spending millions on radical life extension. From cellular reprogramming to blood plasma transfers, how close are they to beating death?
Hyle Editorial·
Bryan Johnson spends $2 million per year trying not to age. His blood test results suggest it might be working. In January 2024, the 46-year-old tech entrepreneur announced that his "pace of aging" had dropped to 0.64—that is, for every year that passes, his body ages only 231 days. He has the heart of a 37-year-old, the skin of a 28-year-old, and the lung capacity of an 18-year-old. But Johnson is merely the most visible face of a far larger phenomenon.
An estimated $30 billion poured into longevity research in 2023 alone, with tech billionaires leading the charge. Jeff Bezos invested $3 billion in Altos Labs, the most well-funded biotech startup in history. Peter Thiel famously takes human growth hormone and invested in Ambrosia, a company that sells young blood plasma transfusions. These aren't eccentric hobbies—they're calculated bets that death is an engineering problem waiting to be solved.
When Altos Labs launched in 2022 with $3 billion in funding, it sent shockwaves through the scientific community. The company wasn't just well-funded—it was aggressively poaching Nobel laureates and leading researchers in cellular reprogramming.
The science behind Altos Labs centers on Yamanaka factors, four proteins that can revert adult cells back into pluripotent stem cells—essentially resetting their biological clock. In mice, this technique has already produced stunning results. In a landmark 2020 study, researchers at Harvard rejuvenated the vision of aged mice by reprogramming their retinal cells. The treated mice not only saw better—they lived longer.
[!INSIGHT] The key insight driving cellular reprogramming is that aging isn't inevitable—it's a program that cells forget to stop running. If we can remind them, the clock might be reversible.
Bezos isn't gambling on speculation. He's betting on a paradigm shift: treating aging as a treatable condition rather than an inevitability. Altos Labs has established research hubs in San Diego, Cambridge, and Tokyo, each focusing on different aspects of cellular rejuvenation.
Bryan Johnson's Blueprint: The N=1 Experiment
While Bezos funds institutional research, Bryan Johnson has turned his own body into a laboratory. His project, Blueprint, involves over 100 daily supplements, strict caloric restriction, and a regimented sleep schedule. He undergoes more than 70,000 blood tests per year.
The results are genuinely striking. Johnson's epigenetic age—measured by DNA methylation patterns—has decreased by approximately 5 years. His inflammatory markers have dropped 80%. Most dramatically, he underwent a plasma exchange with his 17-year-old son, replacing his own plasma with donor plasma in an attempt to dilute factors associated with aging.
“*"I think death is optional. I think we will look back at this moment in history and wonder why we accepted death for so long.”
— Bryan Johnson, 2023
Critics argue that Johnson's approach is unsustainable for the general population. But Johnson counters that he's building a protocol that can eventually be simplified and democratized. His team publishes all data openly, allowing other researchers to analyze and build upon his experiments.
Peter Thiel and Ambrosia: The Blood Hypothesis
Peter Thiel's interest in longevity predates the current boom. In 2006, he famously declared that "death is a problem that can be solved." His investment philosophy reflects this conviction—he's put money into cryonics, human growth hormone therapies, and most controversially, Ambrosia.
Ambrosia Plasma, founded in 2016, offered transfusions of young blood plasma for $8,000 per liter. The science originated from parabiosis experiments, where researchers surgically joined old and young mice, causing the older mice to show signs of rejuvenation. The FDA, however, issued a warning in 2019 stating that young plasma transfusions for anti-aging were unproven and potentially dangerous.
[!NOTE] While Ambrosia has pivoted to focus on plasma-based biomarker testing, the underlying research continues. A 2023 Stanford study found that plasma exchange could reset the immune system's inflammatory signals, though the clinical applications remain unclear.
How Close Are We, Really?
The uncomfortable truth is that no human has been demonstrably age-reversed—yet. The most optimistic researchers believe we're 15-20 years from clinical interventions that could add decades to human lifespan. The pessimists argue we're chasing a mirage.
But three developments suggest the optimists might have the edge:
Validated Biomarkers: For the first time, we can measure biological aging with precision. DNA methylation clocks can predict chronological age within 2-3 years, giving researchers a reliable yardstick.
Converging Therapies: Senolytics (drugs that kill aged cells), NAD+ boosters, mTOR inhibitors, and gene therapies are all showing promise in animal models. The question is no longer whether we can extend life—it's which combination works best.
Serious Money: The 2020s have seen over $50 billion flow into longevity research. This isn't fringe science anymore—it's one of the most well-funded areas of biomedicine.
“[!INSIGHT] The most realistic near-term outcome isn't immortality”
— it's "healthspan extension." If billionaires can compress the period of age-related decline from 20 years to 5, the impact on healthcare systems would be revolutionary.
The Inequality Problem
If these technologies work, they'll initially be available only to the ultra-wealthy. A full plasma exchange protocol costs $200,000. Gene therapies run into seven figures. Even basic senolytic regimens exceed $10,000 annually.
This raises profound ethical questions. Should death remain the great equalizer? If billionaires can buy decades of additional life while others die preventable deaths, the social contract may fray in unprecedented ways.
Some researchers, including those at Altos Labs, argue that the goal is universal access. Just as smartphones trickled down from luxury items to global commodities, longevity therapies will eventually reach everyone. But the timeline for that transition remains deeply uncertain.
Conclusion
The billionaire immortality race isn't science fiction—it's a concerted, well-funded assault on humanity's oldest enemy. Jeff Bezos, Bryan Johnson, and Peter Thiel aren't merely wealthy eccentrics; they're representative of a technological class that refuses to accept biological limits.
Whether they succeed or fail, their investments are accelerating research that could fundamentally transform medicine. The question is no longer whether radical life extension is possible, but when it will arrive—and who will have access to it.
Key Takeaway: The convergence of cellular reprogramming, validated biomarkers, and massive funding suggests that meaningful lifespan extension is likely within two decades. The greater challenge may not be the science, but ensuring that its benefits extend beyond the billionaire class.
Sources: Nature (2023), MIT Technology Review, The Economist "The New Science of Age Reversal" (2024), Altos Labs public filings, Bryan Johnson Blueprint data release, Stanford School of Medicine parabiosis research
This is a Premium Article
Hylē Media members get unlimited access to all premium content. Sign up free — no credit card required.
